Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 15 | 2021 | 242 | 5.370 |
Why?
|
| Mental Disorders | 6 | 2023 | 717 | 2.690 |
Why?
|
| Psychodrama | 2 | 2022 | 2 | 1.510 |
Why?
|
| Graphite | 4 | 2024 | 15 | 1.250 |
Why?
|
| Antipsychotic Agents | 6 | 2019 | 292 | 1.240 |
Why?
|
| Clozapine | 2 | 2019 | 32 | 1.030 |
Why?
|
| Metabolic Diseases | 2 | 2016 | 54 | 0.880 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 682 | 0.860 |
Why?
|
| Help-Seeking Behavior | 1 | 2023 | 10 | 0.850 |
Why?
|
| Neurotransmitter Agents | 2 | 2019 | 41 | 0.800 |
Why?
|
| Mental Health Recovery | 1 | 2022 | 5 | 0.790 |
Why?
|
| Drama | 1 | 2022 | 5 | 0.790 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 131 | 0.770 |
Why?
|
| Insulin | 3 | 2019 | 674 | 0.750 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 192 | 0.730 |
Why?
|
| Mindfulness | 1 | 2021 | 66 | 0.660 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2019 | 5 | 0.660 |
Why?
|
| Methamphetamine | 1 | 2019 | 22 | 0.650 |
Why?
|
| Nitric Oxide | 1 | 2020 | 146 | 0.640 |
Why?
|
| Renin-Angiotensin System | 1 | 2019 | 21 | 0.640 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 25 | 0.640 |
Why?
|
| Art Therapy | 1 | 2019 | 6 | 0.640 |
Why?
|
| Infection Control | 1 | 2020 | 94 | 0.630 |
Why?
|
| Community Health Services | 1 | 2020 | 120 | 0.630 |
Why?
|
| Hospitals, General | 1 | 2018 | 13 | 0.600 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 192 | 0.550 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 205 | 0.550 |
Why?
|
| Health Status Disparities | 1 | 2018 | 137 | 0.530 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 243 | 0.530 |
Why?
|
| Uric Acid | 1 | 2016 | 45 | 0.500 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 41 | 0.490 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 164 | 0.490 |
Why?
|
| Pandemics | 1 | 2020 | 615 | 0.480 |
Why?
|
| Antioxidants | 1 | 2017 | 241 | 0.480 |
Why?
|
| Telemedicine | 1 | 2020 | 307 | 0.480 |
Why?
|
| Dietary Supplements | 1 | 2017 | 223 | 0.470 |
Why?
|
| Mental Health Services | 1 | 2018 | 268 | 0.460 |
Why?
|
| Humans | 22 | 2024 | 59360 | 0.460 |
Why?
|
| Registries | 1 | 2018 | 801 | 0.460 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 788 | 0.410 |
Why?
|
| Double-Blind Method | 4 | 2019 | 715 | 0.410 |
Why?
|
| Quinolones | 1 | 2012 | 27 | 0.400 |
Why?
|
| Piperazines | 1 | 2012 | 74 | 0.390 |
Why?
|
| Microelectrodes | 2 | 2022 | 14 | 0.390 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 203 | 0.370 |
Why?
|
| Body Weight | 3 | 2019 | 368 | 0.330 |
Why?
|
| Cognition | 1 | 2013 | 455 | 0.320 |
Why?
|
| Adult | 9 | 2019 | 15669 | 0.260 |
Why?
|
| Body Composition | 2 | 2019 | 146 | 0.250 |
Why?
|
| Lab-On-A-Chip Devices | 2 | 2022 | 21 | 0.250 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2014 | 379 | 0.240 |
Why?
|
| Male | 10 | 2019 | 27739 | 0.240 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 452 | 0.230 |
Why?
|
| Young Adult | 6 | 2018 | 4267 | 0.230 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 88 | 0.230 |
Why?
|
| Lipoproteins, LDL | 2 | 2016 | 45 | 0.230 |
Why?
|
| Female | 10 | 2019 | 30705 | 0.220 |
Why?
|
| Body Mass Index | 3 | 2019 | 831 | 0.220 |
Why?
|
| Administration, Intranasal | 2 | 2013 | 28 | 0.210 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 2337 | 0.210 |
Why?
|
| Acculturation | 1 | 2023 | 33 | 0.210 |
Why?
|
| Glucose | 2 | 2019 | 445 | 0.210 |
Why?
|
| Adolescent | 5 | 2018 | 5824 | 0.210 |
Why?
|
| Independent Living | 1 | 2023 | 44 | 0.200 |
Why?
|
| Social Stigma | 1 | 2023 | 64 | 0.200 |
Why?
|
| Absorptiometry, Photon | 2 | 2013 | 74 | 0.200 |
Why?
|
| Isoelectric Focusing | 1 | 2022 | 9 | 0.200 |
Why?
|
| Cytokines | 2 | 2019 | 912 | 0.200 |
Why?
|
| Middle Aged | 5 | 2019 | 16317 | 0.200 |
Why?
|
| Patient Care | 1 | 2022 | 78 | 0.190 |
Why?
|
| Biosensing Techniques | 1 | 2023 | 113 | 0.190 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2021 | 25 | 0.180 |
Why?
|
| Focus Groups | 1 | 2022 | 288 | 0.180 |
Why?
|
| Multimorbidity | 1 | 2021 | 43 | 0.180 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2020 | 79 | 0.180 |
Why?
|
| Craving | 1 | 2021 | 35 | 0.180 |
Why?
|
| Social Isolation | 1 | 2020 | 29 | 0.170 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 2373 | 0.170 |
Why?
|
| Mental Health | 1 | 2023 | 335 | 0.170 |
Why?
|
| Electroacupuncture | 1 | 2019 | 3 | 0.170 |
Why?
|
| Arginine | 1 | 2020 | 110 | 0.160 |
Why?
|
| Attention | 1 | 2021 | 146 | 0.160 |
Why?
|
| Psychotic Disorders | 1 | 2021 | 149 | 0.160 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 107 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 450 | 0.150 |
Why?
|
| Exercise Therapy | 1 | 2019 | 99 | 0.150 |
Why?
|
| Oxidative Stress | 1 | 2019 | 279 | 0.140 |
Why?
|
| Triglycerides | 1 | 2019 | 231 | 0.140 |
Why?
|
| Proteins | 1 | 2022 | 730 | 0.130 |
Why?
|
| Schizophrenic Psychology | 2 | 2014 | 65 | 0.130 |
Why?
|
| Aged | 3 | 2018 | 13416 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2019 | 5284 | 0.120 |
Why?
|
| Time Factors | 2 | 2013 | 3617 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2013 | 589 | 0.120 |
Why?
|
| Homocysteine | 1 | 2014 | 33 | 0.120 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 30 | 0.110 |
Why?
|
| Folic Acid | 1 | 2014 | 41 | 0.110 |
Why?
|
| Apolipoprotein A-I | 1 | 2014 | 21 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 326 | 0.110 |
Why?
|
| Risperidone | 1 | 2014 | 24 | 0.110 |
Why?
|
| Adiponectin | 1 | 2013 | 34 | 0.110 |
Why?
|
| Biomarkers | 2 | 2016 | 1306 | 0.110 |
Why?
|
| Homeostasis | 1 | 2016 | 346 | 0.110 |
Why?
|
| Waist Circumference | 1 | 2013 | 45 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1025 | 0.100 |
Why?
|
| Aripiprazole | 1 | 2012 | 5 | 0.100 |
Why?
|
| Inflammation | 1 | 2019 | 1099 | 0.100 |
Why?
|
| Hippocampus | 1 | 2014 | 246 | 0.100 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 111 | 0.100 |
Why?
|
| Benzodiazepines | 1 | 2013 | 94 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2016 | 392 | 0.100 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 96 | 0.100 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 292 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 935 | 0.080 |
Why?
|
| Risk Factors | 1 | 2016 | 4984 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 5128 | 0.060 |
Why?
|
| United States | 1 | 2018 | 7390 | 0.060 |
Why?
|
| Cellular Microenvironment | 1 | 2024 | 20 | 0.060 |
Why?
|
| Hybridization, Genetic | 1 | 2023 | 14 | 0.050 |
Why?
|
| DNA Probes | 1 | 2023 | 35 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2023 | 99 | 0.050 |
Why?
|
| Calcium Signaling | 1 | 2024 | 153 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2024 | 450 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 446 | 0.050 |
Why?
|
| Physical Phenomena | 1 | 2021 | 9 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2021 | 14 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2021 | 68 | 0.050 |
Why?
|
| Copper | 1 | 2021 | 49 | 0.040 |
Why?
|
| Cattle | 1 | 2021 | 304 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2024 | 695 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 806 | 0.040 |
Why?
|
| Animals | 2 | 2024 | 19651 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 21 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2014 | 12 | 0.030 |
Why?
|
| Immunoassay | 1 | 2014 | 67 | 0.030 |
Why?
|
| Chromogranins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 164 | 0.030 |
Why?
|
| Proteomics | 1 | 2014 | 263 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 461 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 654 | 0.020 |
Why?
|